SEP 11, 2026 · PHASE 2 TRIAL
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
ClinicalTrials.gov
Phase II single-arm trial recruiting to evaluate an immune checkpoint inhibitor plus tyrosine kinase inhibitor combination in limited-stage SCLC; no results are posted in this registry record.
Reported
Planned enrollment20
Primary outcome measure 1Progression Free Survival, up to 36 months
Primary outcome measure 2Overall Survival, up to 48 months